These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 39112775)
1. Development of a New Dry Powder Aerosol Synthetic Lung Surfactant Product for Neonatal Respiratory Distress Syndrome (RDS) - Part I: In Vitro Testing and Characterization. Momin MAM; Farkas D; Hindle M; Hall F; DiBlasi RM; Longest W Pharm Res; 2024 Aug; 41(8):1703-1723. PubMed ID: 39112775 [TBL] [Abstract][Full Text] [Related]
2. Development of a New Dry Powder Aerosol Synthetic Lung Surfactant Product for Neonatal Respiratory Distress Syndrome (RDS) - Part II: In vivo Efficacy Testing in a Rabbit Surfactant Washout Model. DiBlasi RM; KenKnight H; Kontoudios N; Farkas D; Momin MAM; Hall F; Hindle M; Longest W Pharm Res; 2024 Sep; 41(9):1827-1842. PubMed ID: 39237797 [TBL] [Abstract][Full Text] [Related]
3. Development of a High-Dose Infant Air-Jet Dry Powder Inhaler (DPI) with Passive Cyclic Loading of the Formulation. Howe C; Momin MAM; Aladwani G; Hindle M; Longest PW Pharm Res; 2022 Dec; 39(12):3317-3330. PubMed ID: 36253630 [TBL] [Abstract][Full Text] [Related]
4. Development and Characterization of Excipient Enhanced Growth (EEG) Surfactant Powder Formulations for Treating Neonatal Respiratory Distress Syndrome. Boc S; Momin MAM; Farkas DR; Longest W; Hindle M AAPS PharmSciTech; 2021 Apr; 22(4):136. PubMed ID: 33860409 [TBL] [Abstract][Full Text] [Related]
5. New Air-Jet Dry Powder Insufflator for High-Efficiency Aerosol Delivery to Rats. Pangeni R; Hassan AAM; Farkas D; Sudarjat H; Longest W; Hindle M; Xu Q Mol Pharm; 2023 Apr; 20(4):2207-2216. PubMed ID: 36938947 [TBL] [Abstract][Full Text] [Related]
6. Initial Development of an Air-Jet Dry Powder Inhaler for Rapid Delivery of Pharmaceutical Aerosols to Infants. Howe C; Hindle M; Bonasera S; Rani V; Longest PW J Aerosol Med Pulm Drug Deliv; 2021 Feb; 34(1):57-70. PubMed ID: 32758026 [No Abstract] [Full Text] [Related]
7. Near Elimination of In Vitro Predicted Extrathoracic Aerosol Deposition in Children Using a Spray-Dried Antibiotic Formulation and Pediatric Air-Jet DPI. Farkas D; Thomas ML; Hassan A; Bonasera S; Hindle M; Longest W Pharm Res; 2023 May; 40(5):1193-1207. PubMed ID: 35761163 [TBL] [Abstract][Full Text] [Related]
8. Advancement of the Infant Air-Jet Dry Powder Inhaler (DPI): Evaluation of Different Positive-Pressure Air Sources and Flow Rates. Howe C; Momin MAM; Farkas DR; Bonasera S; Hindle M; Longest PW Pharm Res; 2021 Sep; 38(9):1615-1632. PubMed ID: 34462876 [TBL] [Abstract][Full Text] [Related]
9. Efficient Nose-to-Lung (N2L) Aerosol Delivery with a Dry Powder Inhaler. Longest PW; Golshahi L; Behara SR; Tian G; Farkas DR; Hindle M J Aerosol Med Pulm Drug Deliv; 2015 Jun; 28(3):189-201. PubMed ID: 25192072 [TBL] [Abstract][Full Text] [Related]
11. Efficacy, dose-response, and aerosol delivery of dry powder synthetic lung surfactant treatment in surfactant-deficient rabbits and premature lambs. Walther FJ; Waring AJ; Otieno M; DiBlasi RM Respir Res; 2022 Apr; 23(1):78. PubMed ID: 35379243 [TBL] [Abstract][Full Text] [Related]
12. Advancement of a Positive-Pressure Dry Powder Inhaler for Children: Use of a Vertical Aerosolization Chamber and Three-Dimensional Rod Array Interface. Farkas D; Bonasera S; Bass K; Hindle M; Longest PW Pharm Res; 2020 Aug; 37(9):177. PubMed ID: 32862295 [TBL] [Abstract][Full Text] [Related]
13. Development of an Inline Dry Powder Inhaler for Oral or Trans-Nasal Aerosol Administration to Children. Farkas D; Hindle M; Bonasera S; Bass K; Longest W J Aerosol Med Pulm Drug Deliv; 2020 Apr; 33(2):83-98. PubMed ID: 31464559 [No Abstract] [Full Text] [Related]
14. Performance of Low Air Volume Dry Powder Inhalers (LV-DPI) when Aerosolizing Excipient Enhanced Growth (EEG) Surfactant Powder Formulations. Boc S; Momin MAM; Farkas DR; Longest W; Hindle M AAPS PharmSciTech; 2021 Apr; 22(4):135. PubMed ID: 33860378 [TBL] [Abstract][Full Text] [Related]
15. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried cyclosporine A multifunctional particles for dry powder inhalation aerosol delivery. Wu X; Zhang W; Hayes D; Mansour HM Int J Nanomedicine; 2013; 8():1269-83. PubMed ID: 23569375 [TBL] [Abstract][Full Text] [Related]
16. Excipient Enhanced Growth Aerosol Surfactant Replacement Therapy in an Kamga Gninzeko FJ; Valentine MS; Tho CK; Chindal SR; Boc S; Dhapare S; Momin MAM; Hassan A; Hindle M; Farkas DR; Longest PW; Heise RL J Aerosol Med Pulm Drug Deliv; 2020 Dec; 33(6):314-322. PubMed ID: 32453638 [No Abstract] [Full Text] [Related]
17. Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer. Meenach SA; Anderson KW; Zach Hilt J; McGarry RC; Mansour HM Eur J Pharm Sci; 2013 Jul; 49(4):699-711. PubMed ID: 23707466 [TBL] [Abstract][Full Text] [Related]
18. Advancement of a high-dose infant air-jet dry powder inhaler (DPI) with passive cyclic loading: Performance tuning for different formulations. Howe C; Momin MAM; Aladwani G; Strickler S; Hindle M; Longest W Int J Pharm; 2023 Aug; 643():123199. PubMed ID: 37406945 [TBL] [Abstract][Full Text] [Related]
19. Characterization of excipient enhanced growth (EEG) tobramycin dry powder aerosol formulations. Hassan A; Farkas D; Longest W; Hindle M Int J Pharm; 2020 Dec; 591():120027. PubMed ID: 33130220 [TBL] [Abstract][Full Text] [Related]
20. High-performing dry powder inhalers of paclitaxel DPPC/DPPG lung surfactant-mimic multifunctional particles in lung cancer: physicochemical characterization, in vitro aerosol dispersion, and cellular studies. Meenach SA; Anderson KW; Hilt JZ; McGarry RC; Mansour HM AAPS PharmSciTech; 2014 Dec; 15(6):1574-87. PubMed ID: 25139763 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]